Department of Surgical Oncology, Institut Claudius Regaud, Toulouse University Cancer Institute (IUCT) - Oncopole, Toulouse, France.
Gynecological Oncology Unit, La Paz Investigation Institute (IdiPAZ), La Paz University Hospital, Madrid, Spain.
Gynecol Oncol. 2022 Jul;166(1):8-17. doi: 10.1016/j.ygyno.2022.05.002. Epub 2022 May 12.
To assess the impact on survival of major postoperative complications and to identify the factors associated with these complications in patients with advanced ovarian cancer after cytoreductive surgery.
We designed a retrospective multicenter study collecting data from patients with IIIC-IV FIGO Stage ovarian cancer who had undergone either primary debulking surgery (PDS), early interval debulking surgery (IDS) after 3-4 cycles of neoadjuvant chemotherapy, or delayed debulking surgery (DDS) after 6 cycles, with minimal or no residual disease, from January 2008 to December 2015. Univariable and multivariable analyses were conducted to identify factors associated with major surgical complications (≥Grade 3). We assessed disease-free survival (DFS) and overall survival (OS) rates according to the occurrence of major postoperative complications.
549 women were included. The overall rate of major surgical complications was 22.4%. Patients who underwent PDS had a higher rate of major complications (28.6%) than patients who underwent either early IDS (23.2%) or DDS (14.0%). Multivariable analysis revealed that extensive peritonectomy and surgical timing were associated with the occurrence of major complications. Median DFS and OS were 16.9 months (95%CI = [13.7-18.4]) and 48.0 months (95%CI = [37.2-73.1]) for the group of patients with major complications, and 20.1 months (95%CI = [18.6-22.4]) and 56.7 months (95%CI = [51.2-70.4]) for the group without major complications. Multivariable analysis revealed that major surgical complications were significantly associated with DFS, but not with OS.
Patients who experienced major surgical complications had reduced DFS, compared with patients without major morbidity. Extensive peritonectomy and surgical timing were predictive factors of postoperative morbidity.
评估主要术后并发症对生存的影响,并确定在接受新辅助化疗 3-4 周期后行初次肿瘤细胞减灭术(PDS)、早期间隔肿瘤细胞减灭术(IDS)或 6 周期后行延迟肿瘤细胞减灭术(DDS)且残余病灶微小或无残余病灶的晚期卵巢癌患者中与这些并发症相关的因素。
我们设计了一项回顾性多中心研究,收集了 2008 年 1 月至 2015 年 12 月期间接受初次肿瘤细胞减灭术(PDS)、新辅助化疗 3-4 周期后行早期间隔肿瘤细胞减灭术(IDS)或 6 周期后行延迟肿瘤细胞减灭术(DDS)且残余病灶微小或无残余病灶的 IIIC-IV 期FIGO 卵巢癌患者的资料。采用单变量和多变量分析确定与主要手术并发症(≥3 级)相关的因素。我们根据主要术后并发症的发生情况评估无病生存(DFS)和总生存(OS)率。
共纳入 549 例患者。主要手术并发症的总体发生率为 22.4%。行 PDS 的患者主要并发症发生率(28.6%)高于行早期 IDS(23.2%)或 DDS(14.0%)的患者。多变量分析显示,广泛腹膜切除术和手术时机与主要并发症的发生有关。主要并发症组的中位 DFS 和 OS 分别为 16.9 个月(95%CI=[13.7-18.4])和 48.0 个月(95%CI=[37.2-73.1]),无主要并发症组的中位 DFS 和 OS 分别为 20.1 个月(95%CI=[18.6-22.4])和 56.7 个月(95%CI=[51.2-70.4])。多变量分析显示,主要手术并发症与 DFS 显著相关,但与 OS 无关。
与无主要并发症患者相比,发生主要手术并发症的患者 DFS 降低。广泛腹膜切除术和手术时机是术后发病率的预测因素。